16815313

Source:http://linkedlifedata.com/resource/pubmed/id/16815313

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0000956, umls-concept:C0001721, umls-concept:C0017431, umls-concept:C0449438, umls-concept:C1332829, umls-concept:C1428184, umls-concept:C1704675, umls-concept:C2917212
pubmed:issue	1
pubmed:dateCreated	2006-7-3
pubmed:abstractText	Our objective was to assess the effects of VKORC1 and CYP2C9 genotypes on severe overanticoagulation and time to achieve stability and their contributions to dose requirement during the initial phase of acenocoumarol treatment.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16815313-16815312
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372741
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acenocoumarol, http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants, http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases, http://linkedlifedata.com/resource/pubmed/chemical/CYP2C9 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases, http://linkedlifedata.com/resource/pubmed/chemical/Warfarin, http://linkedlifedata.com/resource/pubmed/chemical/vitamin K epoxidase
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0009-9236
pubmed:author	pubmed-author:BrasséBjorn PBP, pubmed-author:ChahidYoussefY, pubmed-author:EgbertsAntoine C GAC, pubmed-author:RoijersJanine F MJF, pubmed-author:SchalekampTomT, pubmed-author:de BoerAnthoniusA, pubmed-author:de Vries-GoldschmedingHannekeH, pubmed-author:van Geest-DaalderopJohanna H HJH, pubmed-author:van WijkEduard MEM
pubmed:issnType	Print
pubmed:volume	80
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	13-22
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:16815313-Acenocoumarol, pubmed-meshheading:16815313-Aged, pubmed-meshheading:16815313-Anticoagulants, pubmed-meshheading:16815313-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:16815313-Blood Coagulation, pubmed-meshheading:16815313-Clinical Trials as Topic, pubmed-meshheading:16815313-Drug Interactions, pubmed-meshheading:16815313-Female, pubmed-meshheading:16815313-Follow-Up Studies, pubmed-meshheading:16815313-Genotype, pubmed-meshheading:16815313-Humans, pubmed-meshheading:16815313-International Normalized Ratio, pubmed-meshheading:16815313-Male, pubmed-meshheading:16815313-Middle Aged, pubmed-meshheading:16815313-Mixed Function Oxygenases, pubmed-meshheading:16815313-Multicenter Studies as Topic, pubmed-meshheading:16815313-Netherlands, pubmed-meshheading:16815313-Pharmacogenetics, pubmed-meshheading:16815313-Polymorphism, Genetic, pubmed-meshheading:16815313-Warfarin
pubmed:year	2006
pubmed:articleTitle	VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
pubmed:affiliation	Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. t.schalekamp@pharm.uu.nl
pubmed:publicationType	Journal Article